Acquisition of ORAL TOLVAPTAN (AUE 202600845) from Lab. Otsuka for ULSASI for the year 2026

This tender concerns the acquisition of the pharmaceutical product Oral Tolvaptan, identified by the code AUE 202600845. The supply is specifically for ULSASI (Unidade Local de Saúde do Alto Minho, E.P.E.) and is intended for the year 2026. The procurement is likely being conducted through a direct agreement or a specific framework contract with the manufacturer, Otsuka Laboratory. Oral Tolvaptan is a medication used to treat conditions such as hyponatremia associated with heart failure or SIADH. This acquisition ensures that ULSASI has access to this essential medication for its patients requiring such treatment, maintaining continuity of care for specific medical needs throughout the designated year.

This is a supplies contract in the health and medical services, Research and general supplies sectors, with a focus on Laboratories. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 24,303.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.